By Fineline Cube 
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean company exclusive commercialization rights to its clobetasol propionate ophthalmic suspension, 0.05% (APP13007), in Latin America. Formosa will receive an undisclosed amount of upfront payment and milestone payments.
Drug Overview and Mechanism
APP13007 was approved in the United States in March 2024 for the treatment of post-operative inflammation and pain following ocular surgery. The drug features clobetasol propionate, a superpotent corticosteroid, as its active ingredient. It offers a convenient dosing regimen of twice daily for 14 days, providing rapid and sustained relief of inflammation and pain.
Commercial and Development Milestones
This agreement marks a significant step in Formosa Pharmaceuticals’ international expansion strategy. By partnering with Laboratorios Saval, Formosa aims to leverage Saval’s market presence and distribution capabilities to enhance the accessibility of APP13007 in Latin America.-Fineline Info & Tech